Tabriz University of Medical Sciences Journal of Cardiovascular and Thoracic Research 2008-5117 14 4 2022 12 31 COVID-19 in heart transplant recipients 258 262 10.34172/jcvtr.2022.31583 EN Sepideh Taghavi https://orcid.org/0000-0002-3129-0077 Hoda Raffiei Jelodar https://orcid.org/0000-0002-4824-4632 Ali Rafati https://orcid.org/0000-0001-5578-9668 Nasim Naderi https://orcid.org/0000-0001-6067-040X Marzieh Mirtajaddini https://orcid.org/0000-0003-4842-6230 Ahmad Amin Leili Valizadeh Razieh Omidvar Monireh Kamali Soroush Naseh Journal Article 10.34172/jcvtr.2022.31583 2022 06 06 2022 11 20 Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.